Syngene biologics facility to be operational for US, European customers from mid-year
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Both organisations enter into a long- term collaboration to expand patient access in India
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
More than 10,000 scientific publications containing EUDRAGIT
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
It is the first autotaxin inhibitor to be investigated in cancer patients
Subscribe To Our Newsletter & Stay Updated